3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Dexamethasone
374
Lenalidomide
206
Bortezomib
201
Cyclophosphamide
178
Melphalan
135
Calcium Dobesilate
120
daratumumab
107
pomalidomide
74
carfilzomib
74
fludarabine phosphate
71
Peripheral Blood Stem Cell Transplantation
66
Thalidomide
57
Filgrastim
57
Mycophenolic Acid
56
Busulfan
55
Tacrolimus
48
Granulocyte Colony-Stimulating Factor
47
ixazomib
45
fludarabine
45
Whole-Body Irradiation
44
dexamethasone acetate
36
Cyclosporine
35
isatuximab
34
Etoposide
34
Antilymphocyte Serum
32
dexamethasone 21-phosphate
30
elotuzumab
28
auricularum
27
Prednisone
27
plerixafor
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
crexavibart
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn